SCHEMBL14714742

SCHEMBL14714742

O=C(NC(C(=O)NO)C(=O)NCCCc1ccccc1)c1ccc(-c2ccc(OCCO)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.49
RAB9A P51151 6/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MMP8 P22894 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
NR1H4 Q96RI1 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14714750 0.94 MEN1 (0.57) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL14715199 0.89 NPC1 (0.51) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL14714737 0.88 KLKB1 (0.51) NPC1RAB9AKMT2AMEN1HDAC3
SCHEMBL14714981 0.86 ANPEP (0.49) NPC1
SCHEMBL14715049 0.84 PPARG (0.51)
SCHEMBL14714895 0.83 PPARG (0.46) NPC1RAB9AKMT2AMEN1
SCHEMBL14714497 0.83 PPARG (0.51) NPC1RAB9ASMN1; SMN2MAPTNFKB1
SCHEMBL14714958 0.83 RAB9A (0.52) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL14714713 0.83 USP2 (0.46) NPC1
SCHEMBL14715425 0.81 PPARG (0.50) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 NPC1 3272/4885RAB9A 2523/4885KMT2A 361/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 NPC1 3272/4885RAB9A 2523/4885KMT2A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.